Patent · US Active

Mannheimia haemolytica vector

US12214031B2 · kind B2 · utility

0Cited by
2References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 2, 2023
Grant dateFeb 4, 2025
Priority date
Expiry dateMay 2, 2043

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/543
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.